Drugs / EXEPORFINIUM
EXEPORFINIUM
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01592214 | Aug 2012 → Aug 2015 | staphylococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02282605 | Sep → Nov 2014 | staphylococcus aureus infection | Destiny Pharma Plc | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03915470 | Aug 2019 → Jan 2021 | staphylococcus aureus infection | Destiny Pharma Plc | Completed | Met primary |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXEPORFINIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3824393 ↗ |
| Known as | 5,15-bis-\[4-(3-Trimethylammonio-propyloxy)-phenyl\]-porphyrin dichloride | “All subjects will receive intranasal applications of 5,15-bis-\[4-(3-Trimethylammonio-propyloxy)-phenyl\]-porphyrin dichloride (XF-73).” NCT01592214 ↗ |
| Known as | Chlorure d'exeporfinium | ChEMBL registry synonym — accepted as the source's own label CHEMBL3824393 ↗ |
| Known as | Cloruro de exeporfinio | ChEMBL registry synonym — accepted as the source's own label CHEMBL3824393 ↗ |
| Known as | Exeporfinium cation | ChEMBL registry synonym — accepted as the source's own label CHEMBL3824393 ↗ |
| Known as | Exeporfinium chloride | “Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery” PMID 36951472 ↗ Mar 2023 |
| Known as | Exeporfinium ion | ChEMBL registry synonym — accepted as the source's own label CHEMBL3824393 ↗ |
| Known as | XF-73 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01592214 ↗ |
| Known as | XF-73 CHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3824393 ↗ |
| Modality | Other / unclassified | “XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.” NCT03915470 ↗ |
| Route | Intranasal | “XF-73 nasal gel will be applied to each naris” NCT02282605 ↗ |